健康元(600380.SH):注射用比阿培南獲得藥品註冊證書
格隆匯6月13日丨健康元(600380.SH)公佈,公司全資子公司深圳市海濱製藥有限公司(簡稱:深圳海濱)收到國家藥品監督管理局核准簽發的《藥品註冊證書》。
深圳海濱於2021年12月首次提交注射用比阿培南(以下簡稱:本品)上市許可申請,受理號為CYHS2102250。注射用比阿培南是《國家基本醫療保險、工傷保險和生育保險藥品目錄》(醫保發〔2023〕5號)乙類品種,適用於治療由敏感細菌所引起的敗血症、肺炎、肺部膿腫、急性支氣管炎、慢性支氣管炎急性發作、難治性膀胱炎、腎盂腎炎、腹膜炎和盆腔炎。比阿培南為新型碳青黴烯類抗生素,通過抑制細菌細胞壁的合成而發揮抗菌作用,對革蘭陽性、革蘭陰性的需氧和厭氧菌有廣譜抗菌活性。與其他碳青黴烯類相比,比阿培南的腎毒性、中樞神經系統毒性極低,不良反應相對較少。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.